Published in Oncotarget on November 03, 2015
Targeting oncogenic PLCE1 by miR-145 impairs tumor proliferation and metastasis of esophageal squamous cell carcinoma. Oncotarget (2016) 0.86
Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p) coordinately targeted MTDH in lung squamous cell carcinoma. Oncotarget (2016) 0.82
MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis. J Hum Genet (2016) 0.78
DDX3 Represses Stemness by Epigenetically Modulating Tumor-suppressive miRNAs in Hepatocellular Carcinoma. Sci Rep (2016) 0.76
Mir 145/143: tumor suppressor, oncogenic microenvironmental factor or ...both? Aging (Albany NY) (2016) 0.76
Epigenetically regulated miR-145 suppresses colon cancer invasion and metastasis by targeting LASP1. Oncotarget (2016) 0.75
Altered expression of miRNAs and methylation of their promoters are correlated in neuroblastoma. Oncotarget (2016) 0.75
Advances in decoding breast cancer brain metastasis. Cancer Metastasis Rev (2016) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet (2009) 16.58
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
miRWalk--database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform (2011) 8.50
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol (2010) 6.67
p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A (2009) 5.05
Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol (2004) 4.71
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer (2002) 3.98
Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer (2012) 2.74
MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res (2009) 2.64
The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol (2011) 2.16
EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Sci Signal (2010) 2.16
Multidisciplinary management of brain metastases. Oncologist (2007) 2.15
Epidemiology of brain metastases. Curr Oncol Rep (2012) 2.09
DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene (2011) 1.76
Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene (2012) 1.58
Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One (2011) 1.55
MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol (2011) 1.42
The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene (2012) 1.38
Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene (2012) 1.35
miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis (2012) 1.33
MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell Adh Migr (2013) 1.31
miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res (2010) 1.29
MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci (2010) 1.25
EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes. Am J Physiol Gastrointest Liver Physiol (2004) 1.20
MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle (2012) 1.20
miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer (2014) 1.17
MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLoS One (2013) 1.15
miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol Med (2012) 1.14
Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. FEBS Lett (2014) 1.07
Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing. Mol Cancer Res (2013) 1.02
Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. Oncogene (2013) 1.02
Molecular pathways: microRNAs as cancer therapeutics. Clin Cancer Res (2012) 1.01
OCT4 regulates epithelial-mesenchymal transition and its knockdown inhibits colorectal cancer cell migration and invasion. Oncol Rep (2012) 0.98
microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4. Oncol Rep (2011) 0.97
Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. Ann Oncol (2013) 0.95
miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells. Int J Oncol (2013) 0.95
Downregulation of microRNAs 145-3p and 145-5p is a long-term predictor of postmenopausal breast cancer risk: The ORDET prospective study. Cancer Epidemiol Biomarkers Prev (2014) 0.93
MicroRNA expression profiling of thymic epithelial tumors. Lung Cancer (2014) 0.91
Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. Cancer Treat Rev (2014) 0.89
Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene? Tumour Biol (2014) 0.87
Tumor suppressor microRNAs: a novel non-coding alliance against cancer. FEBS Lett (2014) 1.08
Downregulation of microRNAs 145-3p and 145-5p is a long-term predictor of postmenopausal breast cancer risk: The ORDET prospective study. Cancer Epidemiol Biomarkers Prev (2014) 0.93
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. Br J Pharmacol (2016) 0.91
Tumor Cell Invasion Can Be Blocked by Modulators of Collagen Fibril Alignment That Control Assembly of the Extracellular Matrix. Cancer Res (2016) 0.83
Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy. J Pathol (2016) 0.81
MicroRNAs: short non-coding players in cancer chemoresistance. Mol Cell Ther (2014) 0.78
ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Res (2015) 0.78
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors. Oncotarget (2016) 0.75
Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities. Cell Discov (2017) 0.75
Dietary Protective Effects Against Hepatocellular Carcinoma Development in Mdr2-/- Knockout Mice. In Vivo (2016) 0.75
[Basic principles of signal transduction]. Onkologie (2005) 0.75
Pancreatic cancer ascites xenograft-an expeditious model mirroring advanced therapeutic resistant disease. Oncotarget (2017) 0.75
CRISPR-assisted receptor deletion reveals distinct roles for ERBB2 and ERBB3 in skin keratinocytes. FEBS J (2017) 0.75
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers. Cell (2020) 0.75